) Studies proposed for the first year of the Program Project Grant in projects 1-5 will require 297 marrow, 295 peripheral blood, 40 mobilized blood, 460 umbilical cord blood units and 15 bone samples for the proposed investigations (TABLES 1-6). These samples will be distributed among the laboratories of the project leaders, core directors and collaborators for assessment of phenotype, progenitor content, lymphocyte studies, quantitation of BCR/ABL, quantitation of the retro viral vector LN, inverse PCR for LN, and quantization of donor DNA. The """"""""Cell Therapy and Monitoring Core"""""""" (Core C) will support a centralized effort to procure and to distribute samples required for experiments proposed in Projects 1-5 to the appropriate research laboratories. Core C personnel will monitor patient entry into clinical trials and obtain required samples in a proactive fashion. Samples will be logged, and minimal processing (e.g., preparation of mononuclear cell fractions) performed under standard conditions. When appropriate, samples will be subjected to rate controlled freezing and stored in liquid nitrogen in a central facility under the supervision of Core C personnel. Either fresh or frozen samples will be delivered to the appropriate research laboratories. To centralize specific analyses required in each of the four clinical trials (Projects 2-5), Core C will monitor detection of transduced genes and allogeneic cells using quantitative molecular techniques. Core C will support and coordinate shared resources required for the delivery of the experimental therapies proposed in this Program Project. These efforts will be supported by the core director, Dr. Jeffrey Miller, who is also an active investigator and research project leader (Project 4). The Cell Therapy and Monitoring Core will serve as a resource for the entire program project to provide organization, integration, quality control and oversight of research samples coordinated by a single responsible core director.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-08
Application #
6652739
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-08-26
Project End
2003-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Taraseviciute, Agne; Tkachev, Victor; Ponce, Rafael et al. (2018) Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov 8:750-763
Felices, Martin; Lenvik, Alexander J; McElmurry, Ron et al. (2018) Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 3:
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Pennell, Christopher A; Barnum, Jessie L; McDonald-Hyman, Cameron S et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther 26:1423-1434
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527

Showing the most recent 10 out of 395 publications